Autolus Therapeutics Reports Officer/Director Changes, Comp. Arrangements

TL;DR

**Autolus Therapeutics just reported leadership changes and new compensation plans.**

AI Summary

Autolus Therapeutics plc filed an 8-K on January 10, 2024, reporting an event that occurred on January 9, 2024, related to the departure or election of directors or officers and their compensatory arrangements. The filing also included a Regulation FD Disclosure and information on financial statements and exhibits. This matters to investors because changes in leadership and executive compensation can signal shifts in company strategy or financial health, potentially impacting future stock performance.

Why It Matters

Changes in executive leadership and compensation can influence a company's strategic direction and operational efficiency, directly affecting investor confidence and stock valuation.

Risk Assessment

Risk Level: medium — Changes in leadership can introduce uncertainty, but the specific details of the changes and compensation are not provided in this summary, making the impact unclear.

Analyst Insight

Investors should monitor future filings or company announcements from Autolus Therapeutics plc for specific details on the reported leadership changes and compensation arrangements, as these will provide clearer insights into potential strategic shifts and their financial implications.

Key Numbers

• 2024-01-09 — Date of earliest event reported (The date the reported event, such as director changes, occurred.)
• 001-38547 — Commission File Number (Autolus Therapeutics plc's SEC file number.)
• 44 20 3829 6230 — Registrant's telephone number (Contact number for Autolus Therapeutics plc.)

Key Players & Entities

• Autolus Therapeutics plc (company) — the registrant filing the 8-K
• The Nasdaq Global Select Market (company) — exchange where Autolus's American Depositary Shares are registered
• $0.000042 (dollar_amount) — par value per ordinary share of Autolus Therapeutics plc

Forward-Looking Statements

• Further details regarding the specific director/officer changes and compensatory arrangements will be disclosed in subsequent filings or company announcements. (Autolus Therapeutics plc) — high confidence, target: 2024-03-31

FAQ

Key Financial Figures

• $0.000042 — resenting one ordinary share, par value $0.000042 per share AUTL The Nasdaq Global Selec
• $6 — ADSs"), with an exercise price equal to $6.84, the closing price of the Company's

Filing Documents

• autl-20240109.htm (8-K) — 36KB
• pr10jan2024.htm (EX-99.1) — 6KB
• pr10jan2024001.jpg (GRAPHIC) — 208KB
• pr10jan2024002.jpg (GRAPHIC) — 192KB
• 0001730463-24-000004.txt ( ) — 720KB
• autl-20240109.xsd (EX-101.SCH) — 2KB
• autl-20240109_lab.xml (EX-101.LAB) — 23KB
• autl-20240109_pre.xml (EX-101.PRE) — 12KB
• autl-20240109_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 10, 2024, the Company issued a press release announcing the appointment of Mr. Azelby to the Board. The press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein. The information contained in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits d) Exhibits Exhibit No. Description of Exhibit 99.1 Press release dated January 10 , 2024 104 Cover Page Interactive Data File (embedded within XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTOLUS THERAPEUTICS PLC Dated: January 10, 2024 By: /s/Christian Itin Name: Christian Itin Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR